BACKGROUND
AB Science was founded in 2001 by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discovering key mechanisms in life science and developing new drugs targeting these mechanisms to dramatically change the lives of patients in the most unmet medical needs. Since May 2016, the company has a R&D laboratory located at Genopole in Évry.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
AB Science is specialized in the development of highly specific tyrosine kinase inhibitors to treat pathologies with unmet medical needs in the fields of cancer, neurodegenerative disorders and chronic inflammatory diseases. Masitinib, the company’s key compound, is commercialized in veterinary medicine and is approaching commercialization in human medicine. Masitinib displayed off-target immunomodulating properties that the Genopole laboratory studies at a preclinical stage.
CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS
The clinical development of Masitinib for human use is very advanced with 13 phase III trials in progress. Two applications for marketing authorization, one in mastocytosis and the other in amyotrophic lateral sclerosis, were submitted for this product to EMA in 2016.
